Vindesine in the treatment of small cell anaplastic bronchogenic carcinoma.
Vindesine in the treatment of small cell anaplastic bronchogenic carcinoma.
复制标题
长春地辛治疗小细胞间变性支气管癌。
DOI：
--
复制
发表时间：
1981
期刊：
影响因子：
--
通讯作者：
H. Hansen
中科院分区：
文献类型：
--
作者：
K. Osterlind;P. Dombernowsky;P. G. Sørensen;H. Hansen
在小细胞未分化型支气管肺癌患者的II期试验中评价了长春地辛的抗肿瘤活性。所有患者既往均接受过长春新碱、环己亚硝脲、环磷酰胺、VP-16-213、甲氨蝶呤和多柔比星治疗。在一些患者中，原发性肿瘤也接受了放射治疗，一些患者接受了5-FU或甲基苄肼治疗。长春地辛的剂量为4 mg/m2/周，静脉注射，根据血液学和神经系统副作用进行调整。纳入试验的32例患者中有26例可评价。在7例患者（27%）中观察到客观缓解。中位缓解持续时间为35天（范围：28-90天），缓解发生在治疗开始后14天内。由于血液学毒性，80%的患者需要调整长春地斯汀的剂量，而神经毒性使得大约一半的患者需要减少剂量。该研究表明，长春地辛对小细胞支气管癌有活性，在既往接受过大量治疗的患者中，长春新碱明显缺乏临床交叉耐药性。
The antineoplastic activity of vindesine was evaluated in a phase II trial in patients with small cell anaplastic bronchogenic carcinoma. All patients had been treated previously with vincristine, CCNU, cyclophosphamide, VP-16-213, methotrexate, and doxorubicin. In some of the patients, the primary tumor had also been irradiated, and some patients had received 5-FU or procarbazine. The dose of vindesine was 4 mg/m2/week iv, modified according to hematologic and neurologic side effects. Twenty-six of 32 patients included in the trial were evaluable. Objective response was observed in seven patients (27%). The median duration of response was 35 days (range, 28-90), the response occurring within 14 days after initiation of treatment. Dose modification of vindestine was necessary in 80% of the patients because of hematologic toxicity, while neurotoxicity made dose reductions necessary in about one half of the patients. The study demonstrates that vindesine is active against small cell bronchogenic carcinoma, with apparent lack of clinical cross-resistance to vincristine in previously heavily treated patients.